[go: up one dir, main page]

MX2012012992A - Metodos de tratamiento. - Google Patents

Metodos de tratamiento.

Info

Publication number
MX2012012992A
MX2012012992A MX2012012992A MX2012012992A MX2012012992A MX 2012012992 A MX2012012992 A MX 2012012992A MX 2012012992 A MX2012012992 A MX 2012012992A MX 2012012992 A MX2012012992 A MX 2012012992A MX 2012012992 A MX2012012992 A MX 2012012992A
Authority
MX
Mexico
Prior art keywords
treatment methods
antibodies
treatment
vegr
taxanes
Prior art date
Application number
MX2012012992A
Other languages
English (en)
Inventor
Amy C Peterson
Premal H Patel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2012012992A publication Critical patent/MX2012012992A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general a los campos de biología molecular y regulación de factor de crecimiento. Más específicamente, la invención se refiere a terapias para el tratamiento de condiciones patológicas, tales como cáncer.
MX2012012992A 2010-05-14 2011-05-16 Metodos de tratamiento. MX2012012992A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34504410P 2010-05-14 2010-05-14
US34642410P 2010-05-19 2010-05-19
PCT/US2011/036693 WO2011143665A1 (en) 2010-05-14 2011-05-16 Treatment methods

Publications (1)

Publication Number Publication Date
MX2012012992A true MX2012012992A (es) 2012-12-17

Family

ID=44914745

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012992A MX2012012992A (es) 2010-05-14 2011-05-16 Metodos de tratamiento.

Country Status (12)

Country Link
US (1) US20110287003A1 (es)
EP (1) EP2569014A4 (es)
JP (1) JP2013529203A (es)
KR (1) KR20130065655A (es)
CN (1) CN103025353A (es)
AU (1) AU2011252804A1 (es)
BR (1) BR112012027873A2 (es)
CA (1) CA2793545A1 (es)
MX (1) MX2012012992A (es)
RU (1) RU2012154025A (es)
SG (1) SG185426A1 (es)
WO (1) WO2011143665A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513427A (ja) * 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法
AU2012275233A1 (en) 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations
AU2012340826A1 (en) * 2011-11-21 2014-05-29 Genentech, Inc. Purification of anti-c-met antibodies
GB201121924D0 (en) * 2011-12-20 2012-02-01 Fahy Gurteen Labs Ltd Detection of breast cancer
AU2013280644B2 (en) * 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
WO2014047311A1 (en) * 2012-09-19 2014-03-27 Genentech, Inc. Methods and compositions for preventing norleucine misincorporation into proteins
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR101484062B1 (ko) * 2013-06-10 2015-01-20 케이씨더블류 주식회사 플랫 와이퍼 블레이드
TW201622744A (zh) 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CN105884897A (zh) * 2016-04-23 2016-08-24 同济大学苏州研究院 抗c-Met单价抗体慢病毒快速表达及应用
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3762428A4 (en) * 2018-03-09 2021-12-01 The Regents of the University of California POLYTHERAPY FOR CHEMOR-RESISTANT CANCERS
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
JP5933893B2 (ja) * 2006-12-14 2016-06-15 アブラクシス バイオサイエンス， エルエルシー ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法
US20110262436A1 (en) * 2008-10-17 2011-10-27 Genentech, Inc. Treatment method
TW201019961A (en) * 2008-10-17 2010-06-01 Genentech Inc Combination therapy

Also Published As

Publication number Publication date
CN103025353A (zh) 2013-04-03
EP2569014A4 (en) 2013-11-20
RU2012154025A (ru) 2014-06-20
KR20130065655A (ko) 2013-06-19
US20110287003A1 (en) 2011-11-24
WO2011143665A1 (en) 2011-11-17
BR112012027873A2 (pt) 2017-03-21
CA2793545A1 (en) 2011-11-17
AU2011252804A1 (en) 2012-10-04
JP2013529203A (ja) 2013-07-18
EP2569014A1 (en) 2013-03-20
SG185426A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
MX2012012992A (es) Metodos de tratamiento.
GEP201706612B (en) Methods for the treatment of breast cancer
PH12016502066A1 (en) Methods of treating bladder cancer
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
PT2766040T (pt) Pertuzumab, trastuzumab, docetaxel e carboplatina para o tratamento do cancro da mama em fase precoce
IL253947A0 (en) Methods of treating breast cancer with taxane therapy
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
EA201400178A1 (ru) Лечение рака молочной железы
EP3076972A4 (en) Cancer treatment with combination of plinabulin and taxane
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX377729B (es) Métodos para tratamiento del melanoma.
HUE047198T2 (hu) Fitokannabinoidok emlõrák kezelésére
EA201200999A1 (ru) Способы лечения рака молочной железы
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2014002990A (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
IL244884A0 (en) Antibodies conjugated against ly75 for cancer therapy
TW201611831A (en) Novel antitumoral use of CABAZITAXEL
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
GB201608839D0 (en) Biomarkers useful for detectionof types, grades and stages of human breast cancer
WO2012018877A9 (en) Treating breast cancer with anti-il-19 antibody
EP2647383A4 (en) ACCELERATOR OF MAMMARY INCREASE
EP2707720A4 (en) DIAGNOSIS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER AND OVARY
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
EP2870480A4 (en) METHOD FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER

Legal Events

Date Code Title Description
FA Abandonment or withdrawal